THC stock sentiment todayTenet Healthcare Corp
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
THC
Tenet Healthcare CorpAggressive portfolio reshaping and dominance in high-margin ambulatory surgery centers are driving massive earnings beats and multiple expansion.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for THC. Not financial advice.
Price · last 12 months
Gossip
The market is reacting positively to Tenet's strategic shift away from lower-margin inpatient hospitals toward its United Surgical Partners International (USPI) segment. Investors are cheering recent hospital divestitures at high multiples, which are being used to fuel buybacks and deleverage the balance sheet.
- ·Portfolio optimization through hospital sales
- ·USPI segment growth dominance
- ·Consistent 'beat and raise' earnings cycles
- ·Aggressive share repurchase programs
Financial
THC has significantly improved its balance sheet through asset sales, reducing net debt to EBITDA. The shift toward the Ambulatory Surgery Center (ASC) model has structurally improved EBITDA margins and free cash flow generation.
- ·Forward P/E ~12x (Attractive vs historical range)
- ·EBITDA margins expanding toward 20%+
- ·Adjusted EPS growth exceeding 30% YoY
- ·Net Debt/EBITDA leverage reduced below 3.0x
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow hype — the story is loud but nobody with skin in the game is buying.
- ·Insiders sold a net $45.7M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Labor cost inflation for specialized nursing
- ·Dependency on physician recruitment for USPI growth
- ·Potential regulatory shifts in Medicare reimbursement rates
Peer temperature
How direct competitors stack up against THC right now.
- NEUTRALHCAHCA Healthcare
COLDER — while the industry leader, HCA lacks the concentrated growth tailwind of Tenet's pure-play ASC dominance and is trading at a higher valuation.
See full analysis → - NEUTRALUHSUniversal Health Services
COLDER — faces more volatility in its behavioral health segment and lacks the aggressive portfolio reshaping catalysts seen at THC.
See full analysis → - HOTSGRYSurgery Partners, Inc.
WARMER — higher growth potential as a pure-play ASC competitor but carries significantly higher leverage and less diversified cash flow than Tenet.
See full analysis →
- THC+1.3%
- HCA-1.1%
- UHS-1.2%
- SGRY-6.9%
Analyst price target
Consensus average of 16 analysts · median 283.00
Source: StockAnalysis.com · updated 2026-09-02
AI-generated analysis for informational purposes only. Not financial advice.